<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36430203</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>22</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>08</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>2'-Fucosyllactose Inhibits Coxsackievirus Class A Type 9 Infection by Blocking Virus Attachment and Internalisation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">13727</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms232213727</ELocationID><Abstract><AbstractText>Coxsackieviruses, a genus of enteroviruses in the small RNA virus family, cause fatal infectious diseases in humans. Thus far, there are no approved drugs to prevent these diseases. Human milk contains various biologically active components against pathogens. Currently, the potential activity of breast milk components against the coxsackievirus remains unclear. In our study, the inhibitory effect of 16 major human milk components was tested on coxsackievirus class A type 9 isolate (CV-A9), BUCT01; 2'-Fucosyllactose (2'-FL) was identified to be effective. Time-of-addition, attachment internalisation assays, and the addition of 2'-FL at different time points were applied to investigate its specific role in the viral life cycle. Molecular docking was used to predict 2'-FL's specific cellular targets. The initial screening revealed a significant inhibitory effect (99.97%) against CV-A9 with 10 mg/mL 2'-FL, with no cytotoxicity observed. Compared with the control group, 2'-FL blocked virus entry (85%) as well as inhibited viral attachment (48.4%) and internalisation (51.3%), minimising its infection in rhabdomyosarcoma (RD) cells. The cell pre-incubation with 2'-FL exhibited significant inhibition (73.2-99.9%). Extended incubation between cells with 2'-FL reduced CV-A9 infection (93.9%), suggesting that 2'-FL predominantly targets cells to block infection. Molecular docking results revealed that 2'-FL interacted with the attachment receptor α<sub>v</sub>β<sub>6</sub> and the internalisation receptor FCGRT and β<sub>2</sub>M with an affinity of -2.14, -1.87, and -5.43 kcal/mol, respectively. This study lays the foundation for using 2'-FL as a food additive against CV-A9 infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Fuxing</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5217-6281</Identifier><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Ruolan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yangzhen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mengzhe</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Lihua</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Yigang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-8503-8045</Identifier><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Huahao</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5007-2158</Identifier><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022YFC0867500, 2020YFA0712102, BWS21J025, 20SWAQK22</GrantID><Agency>National Key Research and Development Program of China</Agency><Country /></Grant><Grant><GrantID>82151224</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>BUCTZY2022</GrantID><Agency>Fundamental Research Funds for Central Universities</Agency><Country /></Grant><Grant><GrantID>H2021028</GrantID><Agency>H&amp;amp;H Global Research and Technology Center</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>XO2533XO8R</RegistryNumber><NameOfSubstance UI="C031420">2'-fucosyllactose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053585" MajorTopicYN="N">Virus Attachment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="Y">Coxsackievirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2’-fucosyllactose</Keyword><Keyword MajorTopicYN="N">CV-A9</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">milk</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>26</Day><Hour>1</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36430203</ArticleId><ArticleId IdType="pmc">PMC9691179</ArticleId><ArticleId IdType="doi">10.3390/ijms232213727</ArticleId><ArticleId IdType="pii">ijms232213727</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Duijts L., Jaddoe V.W., Hofman A., Moll H.A. Prolonged and exclusive breastfeeding reduces the risk of infectious diseases in infancy. Pediatrics. 2010;126:e18–e25. doi: 10.1542/peds.2008-3256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2008-3256</ArticleId><ArticleId IdType="pubmed">20566605</ArticleId></ArticleIdList></Reference><Reference><Citation>Conzelmann C., Groß R., Meister T.L., Todt D., Krawczyk A., Dittmer U., Stenger S., Münch J., Steinmann E., Müller J.A., et al. Pasteurization Inactivates SARS-CoV-2-Spiked Breast Milk. Pediatrics. 2021;147:e2020031690. doi: 10.1542/peds.2020-031690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2020-031690</ArticleId><ArticleId IdType="pubmed">33087554</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaender S., Heyden J., Friesland M., Ciesek S., Ejaz A., Steinmann J., Steinmann J., Malarski A., Stoiber H., Tsiavaliaris G., et al. Inactivation of hepatitis C virus infectivity by human breast milk. J. Infect. Dis. 2013;208:1943–1952. doi: 10.1093/infdis/jit519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit519</ArticleId><ArticleId IdType="pubmed">24068703</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Heyden E.L., Pretorius E. The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria. Front. Immunol. 2020;11:1221. doi: 10.3389/fimmu.2020.01221.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01221</ArticleId><ArticleId IdType="pmc">PMC7271924</ArticleId><ArticleId IdType="pubmed">32574271</ArticleId></ArticleIdList></Reference><Reference><Citation>Prentice A., Jarjou L.M., Drury P.J., Dewit O., Crawford M.A. Breast-milk fatty acids of rural Gambian mothers: Effects of diet and maternal parity. J. Pediatr. Gastroenterol. Nutr. 1989;8:486–490. doi: 10.1097/00005176-198905000-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005176-198905000-00011</ArticleId><ArticleId IdType="pubmed">2723940</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox A., Marino J., Amanat F., Krammer F., Hahn-Holbrook J., Zolla-Pazner S., Powell R.L. Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk. iScience. 2020;23:101735. doi: 10.1016/j.isci.2020.101735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101735</ArticleId><ArticleId IdType="pmc">PMC7586930</ArticleId><ArticleId IdType="pubmed">33134887</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan H., Hong B., Luo Y., Peng Q., Wang L., Jin X., Chen Y., Hu Y., Shi Y., Li T., et al. The effect of whey protein on viral infection and replication of SARS-CoV-2 and pangolin coronavirus in vitro. Signal Transduct. Target. Ther. 2020;5:275. doi: 10.1038/s41392-020-00408-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00408-z</ArticleId><ArticleId IdType="pmc">PMC7683587</ArticleId><ArticleId IdType="pubmed">33235188</ArticleId></ArticleIdList></Reference><Reference><Citation>Laucirica D.R., Triantis V., Schoemaker R., Estes M.K., Ramani S. Milk Oligosaccharides Inhibit Human Rotavirus Infectivity in MA104 Cells. J. Nutr. 2017;147:1709–1714. doi: 10.3945/jn.116.246090.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.116.246090</ArticleId><ArticleId IdType="pmc">PMC5572490</ArticleId><ArticleId IdType="pubmed">28637685</ArticleId></ArticleIdList></Reference><Reference><Citation>Drobni P., Näslund J., Evander M. Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antivir. Res. 2004;64:63–68. doi: 10.1016/j.antiviral.2004.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2004.05.005</ArticleId><ArticleId IdType="pubmed">15451180</ArticleId></ArticleIdList></Reference><Reference><Citation>Puddu P., Borghi P., Gessani S., Valenti P., Belardelli F., Seganti L. Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection. Int. J. Biochem. Cell Biol. 1998;30:1055–1062. doi: 10.1016/S1357-2725(98)00066-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1357-2725(98)00066-1</ArticleId><ArticleId IdType="pubmed">9785469</ArticleId></ArticleIdList></Reference><Reference><Citation>Superti F., Siciliano R., Rega B., Giansanti F., Valenti P., Antonini G. Involvement of bovine lactoferrin metal saturation, sialic acid and protein fragments in the inhibition of rotavirus infection. Biochim. Biophys. Acta. 2001;1528:107–115. doi: 10.1016/S0304-4165(01)00178-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-4165(01)00178-7</ArticleId><ArticleId IdType="pubmed">11687297</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho C.A.M., Casseb S.M.M., Gonçalves R.B., Silva E.V.P., Gomes A.M.O., Vasconcelos P.F.C. Bovine lactoferrin activity against Chikungunya and Zika viruses. J. Gen. Virol. 2017;98:1749–1754. doi: 10.1099/jgv.0.000849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000849</ArticleId><ArticleId IdType="pubmed">28699858</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng T.Y., Chen L.C., Shyu H.W., Chen S.H., Wang J.R., Yu C.K., Lei H.Y., Yeh T.M. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antivir. Res. 2005;67:31–37. doi: 10.1016/j.antiviral.2005.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2005.03.005</ArticleId><ArticleId IdType="pubmed">15916817</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoemark D.K., Colenso C.K., Toelzer C., Gupta K., Sessions R.B., Davidson A.D., Berger I., Schaffitzel C., Spencer J., Mulholland A.J. Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARS-CoV-2 Spike Protein. Angew. Chem. Int. Ed. Engl. 2021;60:7098–7110. doi: 10.1002/anie.202015639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202015639</ArticleId><ArticleId IdType="pmc">PMC8013358</ArticleId><ArticleId IdType="pubmed">33469977</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroten H., Hanisch F.G., Hansman G.S. Human Norovirus Interactions with Histo-Blood Group Antigens and Human Milk Oligosaccharides. J. Virol. 2016;90:5855–5859. doi: 10.1128/JVI.00317-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00317-16</ArticleId><ArticleId IdType="pmc">PMC4907220</ArticleId><ArticleId IdType="pubmed">27122582</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong P., Ninonuevo M.R., Lee B., Lebrilla C., Bode L. Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) Br. J. Nutr. 2009;101:482–486. doi: 10.1017/S0007114508025804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114508025804</ArticleId><ArticleId IdType="pubmed">19230080</ArticleId></ArticleIdList></Reference><Reference><Citation>Zevgiti S., Zabala J.G., Darji A., Dietrich U., Panou-Pomonis E., Sakarellos-Daitsiotis M. Sialic acid and sialyl-lactose glyco-conjugates: Design, synthesis and binding assays to lectins and swine influenza H1N1 virus. J. Pept. Sci. 2012;18:52–58. doi: 10.1002/psc.1415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psc.1415</ArticleId><ArticleId IdType="pubmed">22052803</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjomäki V., Turkki P., Huttunen M. Infectious Entry Pathway of Enterovirus B Species. Viruses. 2015;7:6387–6399. doi: 10.3390/v7122945.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7122945</ArticleId><ArticleId IdType="pmc">PMC4690868</ArticleId><ArticleId IdType="pubmed">26690201</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikonov O.S., Chernykh E.S., Garber M.B., Nikonova E.Y. Enteroviruses: Classification, Diseases They Cause, and Approaches to Development of Antiviral Drugs. Biochemistry. 2017;82:1615–1631. doi: 10.1134/S0006297917130041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297917130041</ArticleId><ArticleId IdType="pmc">PMC7087576</ArticleId><ArticleId IdType="pubmed">29523062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId><ArticleId IdType="pmc">PMC7054408</ArticleId><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi H., Oda H., Yamauchi K., Abe F. Lactoferrin for prevention of common viral infections. J. Infect. Chemother. 2014;20:666–671. doi: 10.1016/j.jiac.2014.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2014.08.003</ArticleId><ArticleId IdType="pubmed">25182867</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlutti F., Pantanella F., Natalizi T., Frioni A., Paesano R., Polimeni A., Valenti P. Antiviral properties of lactoferrin--a natural immunity molecule. Molecules. 2011;16:6992–7018. doi: 10.3390/molecules16086992.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules16086992</ArticleId><ArticleId IdType="pmc">PMC6264778</ArticleId><ArticleId IdType="pubmed">21847071</ArticleId></ArticleIdList></Reference><Reference><Citation>Campione E., Cosio T., Rosa L., Lanna C., Di Girolamo S., Gaziano R., Valenti P., Bianchi L. Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation. Int. J. Mol. Sci. 2020;21:E4903. doi: 10.3390/ijms21144903.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21144903</ArticleId><ArticleId IdType="pmc">PMC7402319</ArticleId><ArticleId IdType="pubmed">32664543</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeloni S., Ridet J.L., Kusy N., Gao H., Crevoisier F., Guinchard S., Kochhar S., Sigrist H., Sprenger N. Glycoprofiling with micro-arrays of glycoconjugates and lectins. Glycobiology. 2005;15:31–41. doi: 10.1093/glycob/cwh143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/cwh143</ArticleId><ArticleId IdType="pubmed">15342550</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttunen M., Waris M., Kajander R., Hyypiä T., Marjomäki V. Coxsackievirus A9 infects cells via nonacidic multivesicular bodies. J. Virol. 2014;88:5138–5151. doi: 10.1128/JVI.03275-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03275-13</ArticleId><ArticleId IdType="pmc">PMC3993817</ArticleId><ArticleId IdType="pubmed">24574401</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakeel S., Seitsonen J.J., Kajander T., Laurinmäki P., Hyypiä T., Susi P., Butcher S.J. Structural and functional analysis of coxsackievirus A9 integrin αvβ6 binding and uncoating. J. Virol. 2013;87:3943–3951. doi: 10.1128/JVI.02989-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02989-12</ArticleId><ArticleId IdType="pmc">PMC3624221</ArticleId><ArticleId IdType="pubmed">23365426</ArticleId></ArticleIdList></Reference><Reference><Citation>He S.T., Qin H., Guan L., Liu K., Hong B., Zhang X., Lou F., Li M., Lin W., Chen Y., et al. Bovine lactoferrin inhibits SARS-CoV-2 and SARS-CoV-1 by targeting the RdRp complex and alleviates viral infection in the hamster model. J. Med. Virol. :2022. doi: 10.1002/jmv.28281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28281</ArticleId><ArticleId IdType="pmc">PMC9878033</ArticleId><ArticleId IdType="pubmed">36329614</ArticleId></ArticleIdList></Reference><Reference><Citation>Salaris C., Scarpa M., Elli M., Bertolini A., Guglielmetti S., Pregliasco F., Blandizzi C., Brun P., Castagliuolo I. Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro. Nutrients. 2021;13:328. doi: 10.3390/nu13020328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13020328</ArticleId><ArticleId IdType="pmc">PMC7911668</ArticleId><ArticleId IdType="pubmed">33498631</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda M., Sugiyama K., Tanaka T., Tanaka K., Sekihara H., Shimotohno K., Kato N. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem. Biophys. Res. Commun. 1998;245:549–553. doi: 10.1006/bbrc.1998.8481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1998.8481</ArticleId><ArticleId IdType="pubmed">9571193</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara K., Ikeda M., Saito S., Matsumoto S., Numata K., Kato N., Tanaka K., Sekihara H. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol. Res. 2002;24:228. doi: 10.1016/S1386-6346(02)00088-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1386-6346(02)00088-8</ArticleId><ArticleId IdType="pubmed">12393024</ArticleId></ArticleIdList></Reference><Reference><Citation>Swart P.J., Harmsen M.C., Kuipers M.E., Van Dijk A.A., Van Der Strate B.W., Van Berkel P.H., Nuijens J.H., Smit C., Witvrouw M., De Clercq E., et al. Charge modification of plasma and milk proteins results in antiviral active compounds. J. Pept. Sci. 1999;5:563–576. doi: 10.1002/(SICI)1099-1387(199912)5:12&lt;563::AID-PSC226&gt;3.0.CO;2-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1099-1387(199912)5:12&lt;563::AID-PSC226&gt;3.0.CO;2-3</ArticleId><ArticleId IdType="pubmed">10628656</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa K., Motsuchi W., Tanaka S., Dosako S. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn. J. Med. Sci. Biol. 1994;47:73–85. doi: 10.7883/yoken1952.47.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken1952.47.73</ArticleId><ArticleId IdType="pubmed">7853749</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy M.E., Kariwa H., Mizutani T., Yoshimatsu K., Arikawa J., Takashima I. In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch. Virol. 2000;145:1571–1582. doi: 10.1007/s007050070077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s007050070077</ArticleId><ArticleId IdType="pubmed">11003470</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinari A., Pietrantoni A., Ammendolia M.G., Valenti P., Superti F. Inhibitory activity of bovine lactoferrin against echovirus induced programmed cell death in vitro. Int. J. Antimicrob. Agents. 2005;25:433–438. doi: 10.1016/j.ijantimicag.2005.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2005.02.011</ArticleId><ArticleId IdType="pubmed">15848300</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrantoni A., Di Biase A.M., Tinari A., Marchetti M., Valenti P., Seganti L., Superti F. Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides. Antimicrob. Agents Chemother. 2003;47:2688–2691. doi: 10.1128/AAC.47.8.2688-2691.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.47.8.2688-2691.2003</ArticleId><ArticleId IdType="pmc">PMC166106</ArticleId><ArticleId IdType="pubmed">12878543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S., Sato R., Aoki T., Omoe K., Inanami O., Hankanga C., Yamada Y., Tomizawa N., Yasuda J., Sasaki J. Effect of bovine lactoferrin on functions of activated feline peripheral blood mononuclear cells during chronic feline immunodeficiency virus infection. J. Vet. Med. Sci. 2008;70:429–435. doi: 10.1292/jvms.70.429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1292/jvms.70.429</ArticleId><ArticleId IdType="pubmed">18525162</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha S.H., Mehrez M.A., Sitohy M.Z., Abou Dawood A.G., Abd-El Hamid M.M., Kilany W.H. Effectiveness of esterified whey proteins fractions against Egyptian Lethal Avian Influenza A (H5N1) Virol. J. 2010;7:330. doi: 10.1186/1743-422X-7-330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-330</ArticleId><ArticleId IdType="pmc">PMC2998487</ArticleId><ArticleId IdType="pubmed">21092081</ArticleId></ArticleIdList></Reference><Reference><Citation>Inagaki M., Muranishi H., Yamada K., Kakehi K., Uchida K., Suzuki T., Yabe T., Nakagomi T., Nakagomi O., Kanamaru Y. Bovine κ-casein inhibits human rotavirus (HRV) infection via direct binding of glycans to HRV. J. Dairy Sci. 2014;97:2653–2661. doi: 10.3168/jds.2013-7792.</Citation><ArticleIdList><ArticleId IdType="doi">10.3168/jds.2013-7792</ArticleId><ArticleId IdType="pubmed">24612801</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng T.B., Cheung R.C., Wong J.H., Wang Y., Ip D.T., Wan D.C., Xia J. Antiviral activities of whey proteins. Appl. Microbiol. Biotechnol. 2015;99:6997–7008. doi: 10.1007/s00253-015-6818-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-015-6818-4</ArticleId><ArticleId IdType="pmc">PMC7080083</ArticleId><ArticleId IdType="pubmed">26198883</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerman D.L., Doster R.S., Weitkamp J.H., Aronoff D.M., Gaddy J.A., Townsend S.D. Human Milk Oligosaccharides Exhibit Antimicrobial and Antibiofilm Properties against Group B Streptococcus. ACS Infect. Dis. 2017;3:595–605. doi: 10.1021/acsinfecdis.7b00064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.7b00064</ArticleId><ArticleId IdType="pmc">PMC5868341</ArticleId><ArticleId IdType="pubmed">28570820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerman D.L., Craft K.M., Doster R.S., Weitkamp J.H., Aronoff D.M., Gaddy J.A., Townsend S.D. Antimicrobial and Antibiofilm Activity of Human Milk Oligosaccharides against Streptococcus agalactiae, Staphylococcus aureus, and Acinetobacter baumannii. ACS Infect. Dis. 2018;4:315–324. doi: 10.1021/acsinfecdis.7b00183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.7b00183</ArticleId><ArticleId IdType="pmc">PMC6019282</ArticleId><ArticleId IdType="pubmed">29198102</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Monaco M.H., Wang M., Comstock S.S., Kuhlenschmidt T.B., Fahey G.C., Miller M.J., Kuhlenschmidt M.S., Donovan S.M. Human milk oligosaccharides shorten rotavirus-induced diarrhea and modulate piglet mucosal immunity and colonic microbiota. ISME J. 2014;8:1609–1620. doi: 10.1038/ismej.2014.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ismej.2014.10</ArticleId><ArticleId IdType="pmc">PMC4817601</ArticleId><ArticleId IdType="pubmed">24522264</ArticleId></ArticleIdList></Reference><Reference><Citation>Weichert S., Koromyslova A., Singh B.K., Hansman S., Jennewein S., Schroten H., Hansman G.S. Structural Basis for Norovirus Inhibition by Human Milk Oligosaccharides. J. Virol. 2016;90:4843–4848. doi: 10.1128/JVI.03223-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03223-15</ArticleId><ArticleId IdType="pmc">PMC4836343</ArticleId><ArticleId IdType="pubmed">26889023</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore R.E., Xu L.L., Townsend S.D. Prospecting Human Milk Oligosaccharides as a Defense Against Viral Infections. ACS Infect. Dis. 2021;7:254–263. doi: 10.1021/acsinfecdis.0c00807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00807</ArticleId><ArticleId IdType="pmc">PMC7890562</ArticleId><ArticleId IdType="pubmed">33470804</ArticleId></ArticleIdList></Reference><Reference><Citation>Bode L., Kuhn L., Kim H.Y., Hsiao L., Nissan C., Sinkala M., Kankasa C., Mwiya M., Thea D.M., Aldrovandi G.M. Human milk oligosaccharide concentration and risk of postnatal transmission of HIV through breastfeeding. Am. J. Clin. Nutr. 2012;96:831–839. doi: 10.3945/ajcn.112.039503.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.112.039503</ArticleId><ArticleId IdType="pmc">PMC3441110</ArticleId><ArticleId IdType="pubmed">22894939</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Liempt E., Bank C.M., Mehta P., Garciá-Vallejo J.J., Kawar Z.S., Geyer R., Alvarez R.A., Cummings R.D., van Kooyk Y., van Die I. Specificity of DC-SIGN for mannose- and fucose-containing glycans. FEBS Lett. 2006;580:6123–6131. doi: 10.1016/j.febslet.2006.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2006.10.009</ArticleId><ArticleId IdType="pubmed">17055489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramani S., Stewart C.J., Laucirica D.R., Ajami N.J., Robertson B., Autran C.A., Shinge D., Rani S., Anandan S., Hu L., et al. Human milk oligosaccharides, milk microbiome and infant gut microbiome modulate neonatal rotavirus infection. Nat. Commun. 2018;9:5010. doi: 10.1038/s41467-018-07476-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07476-4</ArticleId><ArticleId IdType="pmc">PMC6258677</ArticleId><ArticleId IdType="pubmed">30479342</ArticleId></ArticleIdList></Reference><Reference><Citation>Heikkilä O., Merilahti P., Hakanen M., Karelehto E., Alanko J., Sukki M., Kiljunen S., Susi P. Integrins are not essential for entry of coxsackievirus A9 into SW480 human colon adenocarcinoma cells. Virol. J. 2016;13:171. doi: 10.1186/s12985-016-0619-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-016-0619-y</ArticleId><ArticleId IdType="pmc">PMC5069866</ArticleId><ArticleId IdType="pubmed">27756316</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Zhang G., Liu S., Chen X., Peng R., Dai L., Qu X., Li S., Song H., Gao Z., et al. Human Neonatal Fc Receptor Is the Cellular Uncoating Receptor for Enterovirus B. Cell. 2019;177:1553–1565.e16. doi: 10.1016/j.cell.2019.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.04.035</ArticleId><ArticleId IdType="pmc">PMC7111318</ArticleId><ArticleId IdType="pubmed">31104841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>